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The paradigm of a single gene associated with one specific phenotype and mode of inheritance has been repeatedly challenged.
Genotype-phenotype correlations can often be traced to different mutation types, localization of the variants in distinct protein
domains, or the trigger of or escape from nonsense-mediated decay. Using whole-exome sequencing, we identified homozygous variants
in EMC1 that segregated with a phenotype of developmental delay, hypotonia, scoliosis, and cerebellar atrophy in three families. In addi-
tion, a de novo heterozygous EMC1 variant was seen in an individual with a similar clinical andMRI imaging phenotype. EMC1 encodes
a member of the endoplasmic reticulum (ER)-membrane protein complex (EMC), an evolutionarily conserved complex that has been
proposed to have multiple roles in ER-associated degradation, ER-mitochondria tethering, and proper assembly of multi-pass transmem-
brane proteins. Perturbations of protein folding and organelle crosstalk have been implicated in neurodegenerative processes including
cerebellar atrophy. We propose EMC1 as a gene in which either biallelic or monoallelic variants might lead to a syndrome including
intellectual disability and preferential degeneration of the cerebellum.The endoplasmic reticulum (ER)-membrane protein com-
plex (EMC) family was first identified in yeast as a multi-
protein transmembrane complex containing six subunits,
with a possible function in elimination of misfolded
membrane proteins in the ER.1 Studies in C. elegans suggest
that emc-6 is required for protein folding and that it
possibly modulates ER-associated degradation (ERAD) of
specific proteins.2 More recent studies have implicated
the EMC in facilitating contacts between the ER and
mitochondria, perhaps by modulating the folding or pro-
cessing of proteins directly involved in such tethering.3
The EMC is required for the stable expression of other
multi-pass transmembrane proteins such as rhodopsin,
and its loss has been associated with retinal degeneration
in Drosophila.4 Despite these advances in understanding,
the function of the EMC and its relevance to human dis-
ease remain to be elucidated.
Aberrations of protein folding, the unfolded protein
response, ERAD, and glial lipid droplet accumulation and
reactive oxygen species induced by mitochondrial defects
have been associated with neurodegeneration.5–7 Aberrant
communication between mitochondria and the ER has
been implicated in Alzheimer disease (MIM: 104300)
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[MIM: 605704]), ALS type 16 (MIM: 614373) (SIGMAR1
[MIM: 601978]), Charcot-Marie-Tooth disease (CMT) type
2A (MIM: 609260) (MFN2 [MIM: 608507]), and Parkinson
disease (MIM: 168601) (SNCA [MIM: 163890]).8 Specif-
ically, upregulation of mitochondria-associated ER mem-
brane (MAM) function with increased ER-mitochondrial
communication has been detected in presenilin mutant
cells as well as in fibroblasts from individuals with both
familial and sporadic forms of Alzheimer disease.9 a-synu-
clein, encoded by SNCA and implicated in Parkinson dis-
ease (PD), has recently been shown to localize to MAM
rather than to the mitochondria, and MAM function is
downregulated in cell and mouse models of PD expressing
pathogenic variants of a-synuclein. Early events occurring
in dopaminergic neurons at the level of MAM are hypoth-
esized to possibly cause long-term disturbances that might
lead to PD.10,11
In this study, we report four different families affected
by developmental delay, hypotonia, scoliosis, and cere-
bellar atrophy. All affected individuals had potential path-
ogenic EMC1 variants, including a homozygous frameshift
variant, two homozygous missense variants, and a de novo
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Figure 1. Pedigrees and Sanger Validation and Segregation of the Identified Variants
(A) Family 1.
(B) Family 2. Note the consanguinity.
(C) Family 3. Note the consanguinity.
(D) Family 4. Segregation of the monoallelic variant in EMC1 in individual II-6 demonstrates the variant in the proband but not in his
parents, consistent with a de novo event.
(E–G) Evolutionary conservation of the altered amino acid residue at positions 82 (E), 868 (F), and 471 (G).
(H) Depiction of the conserved domains of EMC1 and location of the variants identified in the four families.sequencing (WES) in the respective families. We char-
acterize the phenotypic features of this syndrome and
propose EMC1 as a gene in which either biallelic (homozy-
gous) or monoallelic (heterozygous) variants might lead to
neurodegenerative disease.
After informedconsentwas given, family1was sequenced
by a trio approach (proband A3, II-1 in Figure 1A and
parents) with an Agilent SureSelect Human All Exon V4
(50 Mb) kit (Agilent Technologies). The individuals in fam-
ilies 2 and 3 provided consent according to the Baylor-Hop-
kins Center for Mendelian Genomics (BHCMG) research
protocol, andWESwasperformedontwo individuals in fam-
ily 2 (BAB3445, III-2 and BAB4742, III- 4 in Figure 1B) and
two individuals in family 3 (BAB6897, III-1 and BAB6896,
III-2 in Figure 1C), according to previously described proto-
cols.12 Individual BH4387_1 (family 4, II-6 in Figure 1D) un-
derwent clinicalWES atBaylor-MiracaGenetics Laboratories
(Baylor College ofMedicine [BCM]), according to the proto-
col described inYanget al.13 Because this didnot reveal apre-
dicted pathogenic variant in any known gene associated
with the phenotype, the family gave consent for research
studies under a protocol approved by the BCM institutional
review board. Parental exome sequencing was obtainedThe Amethrough the BHCMGresearch initiative. In brief, for families
2–4, DNA samples were prepared into Illumina paired-end
libraries and underwent whole-exome capture via the
BCM-HGSC core design (52 Mb, Roche NimbleGen), fol-
lowed by sequencing on the Illumina HiSeq 2000 platform
(Illumina). Averagedepthof coverageonWES for all affected
individuals ranged from ~813 to ~2013. Specifically, in
individual BH4387_1 (family 4, II-6 in Figure 1D), all exons
of EMC1 were covered at an average of 643 or greater
and copy-number variants (CNVs) were analyzed with the
CoNVex and CoNIFER tools. Data produced were aligned
and mapped to the human genome reference sequence
(GenomeReferenceConsortiumGRCh37)with theMercury
pipeline.14 Single-nucleotide variants (SNVs) were called
with theATLAS (an integrativevariant analysispipelineopti-
mized for variant discovery) variant calling method and
SAMtools (the Sequence Alignment/Map) and annotated
with the in-house-developed ‘‘Cassandra’’ annotation pipe-
line that uses ANNOVAR (annotation of genetic variants)
and additional tools and databases.15–17 The GeneMatcher
tool18 facilitated identification of family 1, which has a
homozygous frameshift EMC1 variant (see Supplemental
Note for detailed downstreamWES analysis).rican Journal of Human Genetics 98, 562–570, March 3, 2016 563
Analysis of families 1 and 4 assumed either de novo or
recessive inheritance. Analysis of family 2 assumed a reces-
sive inheritance pattern on the basis of consanguinity,
unaffected parents, and multiple affected members, both
females and males. Family 3 was analyzed for recessive or
X-linked models. We calculated de novo variants by
in silico subtraction of parental variants from the pro-
band’s variants in VCF files and by using the read
depth-of-coverage information extracted from BAM files.
Bioinformatics tools were used to predict conservation
and pathogenicity of candidate variants, and variants
were compared to an internal database (~5,000 exomes)
and publicly available databases such as the 1000Genomes
Project, the NHLBI GO Exome Sequencing Project (ESP)
Exome Variant Server, the Atherosclerosis Risk in Commu-
nities Study (ARIC) Database, and the Exome Aggregation
Consortium (ExAC) database. Amplicons containing the
candidate variants identified by WES were amplified from
genomic DNA via conventional PCR. The promoter region
of EMC1 was amplified in individual BH4387_1 (II-6,
Figure 1D) to assess for intronic variation not detected by
WES. Primers are listed in Table S1. PCR products were
purified with ExoSAP-IT (Affymetrix) and analyzed by
standard Sanger di-deoxy nucleotide sequencing (DNA
Sequencing Core Facility, BCM).
The clinical findings for seven affected individuals from
four families are summarized inTable 1; detailed case reports
canbe found in theSupplementalNoteandphotosareavail-
able in Figure 2. Two families reported known consanguin-
ity and includedmultiple affected individuals; theother two
families each had a single affected individual (Figure 1).
Ancestries were diverse and included European, Turkish,
Saudi Arabian, andHispanic. All affected individuals shared
global developmental delay, ranging from severe (families
1, 2, and 4) to mild-moderate (family 3) (see Supplemental
Note for details). Ophthalmology exam was abnormal in
all families, and included cortical visual impairment (family
1), abnormal visual evokedpotentials andabnormal electro-
retinogram (family 2), esotropia, hyperopia, and astigma-
tism (family 3), and myopia and optic atrophy (family 4).
Additional shared features in three of the families (families
1, 2, and 4) were scoliosis and diminished deep tendon
reflexes (DTRs). Dystonic posturing and increased tone
in the extremities were found in two families (families 1
and 2). Birth and serial postnatal head circumference mea-
surements in affected individuals in family 2 indicated an
acquired microcephaly, with normal head circumferences
at birth (~50th percentile) decreasing to Z scores ranging
from 3.3 to 4 in childhood. Features unique to family 1
included subclinical multifocal electrographic seizures, lar-
yngotracheomalacia, and imperforate anus.
Brain MRI studies (Figure 2) showed cerebellar atrophy
and a foreshortened corpus callosum in all four families.
Affected individuals in families 1, 2, and 4 all had varying
degrees of cerebral atrophy, and affected individuals
in family 1 also had small hippocampi. Sequential MRI
studies at two different ages were available for individuals564 The American Journal of Human Genetics 98, 562–570, March 3in families 1, 2, and 4. These indicated a progression of
brain atrophy, most pronounced in the cerebellum, impli-
cating a neurodegenerative process (Figures 2K and 2L and
2R and 2S).
WES identified a homozygous frameshift variant
(chr1:g.19547308_19547311delAGGA
[c.2619_2622delTCCT; p.Pro874Argfs*21], UCSC Browser
hg19) in EMC1 (GenBank: NM_015047.2) in family 1
(Figure 1A). This variant is located in exon 21 of 23, and
thus might trigger nonsense-mediated decay (NMD) and
cause a loss-of-function allele. RNA and protein from the
affected individual were not available for study. Although
consanguinity was not known in this family, WES data
indicate that this variant lies in a small stretch of absence
of heterozygosity (AOH) spanning ~100 kb (see Supple-
mental Note). A recent study that identified a small shared
region of AOH spanning ~140 kb between families of
common ethnicity estimated a common ancestor approx-
imately 16.2 generations in the past (5 8.7 generations).19
Thus, it might be expected that this EMC1 frameshift
variant could be encountered in the future in additional
families with global developmental delay and progressive
cerebral and cerebellar atrophy.
Homozygous missense variants in EMC1 were identified
in families 2 and 3 (Supplemental Note, Table S2). The
three available affected individuals in family 2 shared
a homozygous variant (chr1:g.19570485G>A [c.245C>T;
p.Thr82Met], hg19), located within a shared AOH region
of ~9.26Mb (Figure S1). This EMC1 variant alters a relatively
conserved amino acid (Figure 1E) froma polar to a nonpolar
residue, has a CADD phred-like score of 29.8, and is pre-
dicted to be deleterious by four of four additional bioinfor-
matics prediction programs (Table S2). This variant has
not been observed in publicly available databases and was
seen only once in a heterozygous state in our internal data-
base. In family 3, homozygous variants in three potential
candidate genes segregated with the phenotype in the
family, including a homozygous missense variant in EMC1
(chr1:g.19547328C>T [c.2602G>A; p.Gly868Arg], hg19)
with a CADD phred-like score of 33 and deleterious predic-
tions in three of four other prediction programs (Table S2).
Notably, a homozygous loss-of-function variant in SMCO2
was also identified, suggesting the potential contribution
of variants to the manifested disease trait at more than one
locus. However, given the involvement of the cerebellum
on neuroimaging and the foreshortened corpus callosum,
findings that are consistent with (yet milder than) the find-
ings in the other three families affected by EMC1 variants
described in this study, we cannot rule out the contribution
of a mild EMC1 allele to the phenotype. This can be viewed
inaccordancewith recentpublications describingdual diag-
noses in individuals13 and particularly the contribution of
multiple loci for recessive disease diagnoses in children
born to consanguineous parents (unpublished data).
Analysis of trio WES in family 4 yielded a number of
rare variants (Table S2), including a single nonsynony-
mous heterozygous de novo variant (chr1:g.19561645C>G, 2016
Table 1. Clinical Features of Individuals with EMC1 Variants
Family 1 Family 2 Family 3 Family 4 No. of
Families
AffectedA3 BAB3445 BAB3446 BAB4742 BAB6896 BAB6897 BH4387_1
Age at last exam 4 years 13 years 5 years 3 years 10 years 12 years 12 years NA
Global
developmental
delay
þ þ þ þ þ þ þ 4/4
Speech delay þ þ þ þ þ þ þ 4/4
Seizures þ (subclinical)       1/4
Scoliosis þ þ þ þ   þ 3/4
Head
circumference:
approximate
Z scorea
1.6 (2 years
9 months)
4 3.8 3.3 0 0 0.34 NA
Dysmorphic
features
short upper lip,
mild hypertelorism,
retrognathia
deep-set
eyes, gingival
hyperplasia,
short philtrum,
retrognathia,
persistent fetal
fingerpads
deep-set eyes,
gingival
hyperplasia,
short philtrum,
retrognathia,
persistent fetal
fingerpads
deep-set eyes,
gingival
hyperplasia,
short philtrum,
retrognathia,
persistent fetal
fingerpads
deep-set eyes,
retrognathia
deep-set
eyes
low anterior
hairline,
dysplastic ears,
gingival
hyperplasia,
micrognathia
NA
Truncal
hypotonia
þ þ þ þ þ  þ 4/4
Increased tone
in extremities
þ þ þ þ    2/4
Diminished
DTRs
þ þ þ þ NR  þ 3/4
Dystonic
posturing
þ þ þ þ    2/4
Abnormal
ophthalmology
exam
cortical visual
impairment
abnormal VEP
and ERG
abnormal VEP
and ERG
abnormal VEP
and ERG
esotropia,
hyperopia,
astigmatism
NR myopia, optic
atrophy
4/4
Cerebellar
atrophy
þ þ þ þ þ NR þ 4/4
Cerebral atrophy þ þ þ þ  NR þ (mild) 3/4
Foreshortened
or atrophic
corpus callosum
þ þ þ þ þ NR þ 4/4
Other clinical
findings
laryngotracheomalacia,
imperforate anus
NR NR NR NR NR vitiligo NA
Variants
in EMC1
c.2619_2622delTCCT
(p.Pro874Argfs*21),
hom.
c.245C>T
(p.Thr82Met),
hom.
c.245C>T
(p.Thr82Met),
hom.
c.245C>T
(p.Thr82Met),
hom.
c.2602G>A
(p.Gly868Arg), hom.
c.1411G>C
(p.Gly471Arg),
de novo
NA
Abbreviations are as follows: DTRs, deep tendon reflexes; ERG, electroretinogram; hom., homozygous; NA, not applicable; NR, not reported; VEP, visual evoked
potential.
aThe age in parentheses indicates the age at which head circumference was measured, if not at last exam.[c.1411G>C; p.Gly471Arg], hg19) in EMC1. The
p.Gly471Arg variant alters a conserved amino acid (Figures
1D and 1G) from a nonpolar neutral residue to a polar basic
residue, has a CADD phred-like score of 28.2, and is pre-
dicted to be deleterious by MutationTaster and LRT (Table
S2). The variant was not observed in any publicly available
database nor in our internal database. All exons of EMC1
were covered at an average of 643 or greater in this indi-
vidual, and no other rare missense variants in EMC1 were
observed. In search of a possible second hit in this gene,
we evaluated the exome read depth data for a CNV andThe Amedid not identify a deletion within or near EMC1. Moreover,
we sequenced the promoter region of EMC1, but no addi-
tional rare variant was identified (data not shown). Using
a combination of in silico tools and literature search, we
were unable to identify any published interactions be-
tween EMC1 and other proteins implicated in numerous
types of cerebellar atrophy or pontocerebellar hypoplasia
(Table S3).
The summation of the molecular data in these four
families with varying degrees of developmental delay
and cerebellar atrophy includes homozygous variants inrican Journal of Human Genetics 98, 562–570, March 3, 2016 565
Figure 2. Facial Features and Midsagittal Brain MRI Sections of Affected Individuals
(A–L) Front and profile photographs of affected individuals from families 1–3 (A–I) and T1-weighted sagittal images (K–L) indicate
progressive cerebellar atrophy, atrophic corpus callosum, and diminished cerebral white matter in family 1, as compared to the control
individual (J). Thick arrow points to cerebellum vermis; thin arrow indicates corpus callosum.
(M–P) T1-weighted (M–O) and T2-weighted (P) sagittal images indicate cerebellar atrophy, cerebral atrophy, and a thin foreshortened
corpus callosum in affected individuals of family 2.
(Q) Atrophy of the superior cerebellar vermis and a foreshortened corpus callosum in family 3.
(R and S) Progressive cerebellar atrophy, mild cerebral atrophy, and foreshortened corpus callosum in family 4.
Identifiers refer to pedigree numbers in Figure 1.EMC1 in three families (c.2619_2622delTCCT, c.245C>T,
and c.2602G>A) and a de novo heterozygous variant
(c.1411G>C) in a fourth family (Figure 1). Common
phenotypic features included progressive neurodegenera-
tion with a predilection for the cerebellum (4/4 families),
global developmental delay with marked speech delay
(4/4 families), scoliosis (3/4 families), truncal hypotonia
(4/4 families), diminished DTRs (4/4 families), dystonic
posturing (2/4 families), and an abnormal ophthalmolog-
ical exam (4/4 families) (Table 1). Serial brain MRI results
from individuals in families 1, 2, and 4 indicated interval
development of cerebellar atrophy, suggesting a progres-
sive neurodegenerative process. Only a single MRI (at the
age of 3 years) was available for an affected individual
from family 3, so we could not evaluate progression of
the atrophy in that family.
Cerebellar atrophy, implying irreversible and progressive
loss of tissue, is typically more pronounced in the cere-
bellar vermis than in the hemispheres20 and can be sub-
grouped into categories based on associated neuroimaging
findings in an effort to direct diagnosis.21 Molecularly,
cerebellar atrophy can involve various mechanisms,566 The American Journal of Human Genetics 98, 562–570, March 3including defective DNA damage response (i.e., ATM
[MIM: 607585] in ataxia telangiectasia [MIM: 208900]),
abnormal DNA single-strand break repair (i.e., TDP1
[MIM: 607198] in spinocerebellar ataxia with axonal
neuropathy-1 [MIM: 607250]),22 aberrant DNA repair
and/or RNA processing (i.e., APTX [MIM: 606350] and
SETX [MIM: 608465] in ataxia with oculomotor apraxia,
types 1 [MIM: 208920] and 2 [MIM: 606002], respec-
tively),23 or protein folding (SACS [MIM: 604490] in
Charlevoix-Saguenay spastic ataxia [MIM: 270550]).23,24
Pontocerebellar hypoplasia, of which some subtypes repre-
sent neurodegeneration starting in utero, is often associ-
ated with defective tRNA splicing.19,25,26
EMC1 is located on chromosome 1p36.13, consists of 23
exons, and encodes a 993 amino acid protein that is one of
ten unique EMC subunits in humans.27 The EMC has been
implicated in ER-mitochondria crosstalk, protein folding,
and possibly in ERAD of specific proteins,1,2 aberrations
of which have all been associated with neurodegenera-
tion.5,6,24,28 Impaired intracellular communication was
recently shown with mutations in COPA (MIM: 601924),
whereby impaired inter-organellar transport, retrograde, 2016
Golgi-to-ER transport, results in increased ER stress and
generation of cytokines and is associated with hereditary
autoimmune-mediated lung disease and arthritis.29 Simi-
larly, perturbed vesicular Golgi-ER transport and resultant
increased ER stress was hypothesized to underlie a pheno-
type of rhabdomyolysis, metabolic crises, and cardiac
arrhythmia associated with mutations in TANGO2,30 high-
lighting the importance of maintaining proper intracel-
lular organelle crosstalk.
EMC1 is ubiquitously expressed and includes two
conserved domains: a quinoprotein alcohol dehydroge-
nase-like domain (PQQ_2) spanning residues 28–242 and
an as-yet-uncharacterized domain of unknown function
1620 (DUF1620) including residues 786–992. The homo-
zygous p.Thr82Met and p.Gly868Arg variants lie in the
PQQ_2 and DUF1620 domains, respectively, whereas the
de novo p.Gly471Arg variant is not located in either
domain (Figure 1H). There has been a single previous
report of a putative association between an EMC1 variant
and human disease. In a family with non-syndromic reti-
nitis pigmentosa, Abu-Safieh et al.31 identified a homozy-
gous missense EMC1 variant (c.430G>A [p.Ala144Thr])
not found in 380 ethnically-matched control individuals.
Given the variable clinical severity in the families reported
herein, in conjunction with support from the literature
regarding the role of EMC1 in rhodopsin biosynthesis,4 it
seems plausible to hypothesize that the p.Ala144Thr
variant identified by Abu-Safieh et al.31 might represent a
mild allele with an isolated ophthalmological phenotype.
Alternatively, the energy demands of the visual system
could make it particularly susceptible to variant alleles
affecting mitochondrial function.
The clinical features encountered in families 3 and 4
were less severe than those seen in families 1 and 2. None-
theless, all individuals for whom serial brain MRIs were
available had evidence of a progressive neurodegenerative
process primarily affecting the cerebellum, suggesting a
unifying molecular pathogenesis in these cases. We were
not able to identify a second mutation in trans with the
de novo c.1411G>C variant in family 4, either by analysis
of the WES data or by Sanger sequencing of the putative
promoter region. Moreover, no CNV was identified within
or in proximity to EMC1. A deep intronic variant could not
be ruled out. We thus propose that EMC1might ultimately
be added to the growing list of genes in which both auto-
somal-recessive and sporadic de novo mutations might
lead to human disease.
Multiple genes exist for which both monoallelic and
biallelic inheritance have been demonstrated and pub-
lished simultaneously32 or in a sequential fashion (Table
S4). Classic Mendelian medical genetics implies that a
specific gene is associated with a phenotype that shows
a consistent pattern of inheritance, and indeed this holds
true in the majority of recognizable gene-disease associa-
tions. Laminopathies, a broad range of phenotypically
distinct disorders associated with mutations in LMNA
(MIM: 150330), could be considered the prototype ofThe Amegenes that harbor variant alleles that could lead to either
dominant or recessive disease traits. The diversity of the
laminopathies, which include premature aging syn-
dromes, lipodystrophies, cardiomyopathies, muscular dys-
trophies, and neuropathies (reviewed in Chojnowski
et al.),33 has been explained by a paralleled diversity of
hypotheses. Differential allelic expression,34 haploinsuffi-
ciency for late-onset phenotypes versus dominant-nega-
tive or toxic gain-of-function in early phenotypes,35 and
digenic inheritance36,37 have all been considered.
Additional examples of genes with both dominant and
recessive forms of inheritance are listed in Table S4. The
phenotype caused by de novo mutations can be more
severe than the recessive phenotype, as with GJB2 ([MIM:
121011] keratitis-icthyosis-deafness versus nonsyndromic
deafness),38 KIF1A ([MIM: 601255] severe intellectual
disability with progressive cerebral and cerebellar atrophy
versus hereditary spastic paraplegia),39 and MAB21L2
([MIM: 604357] microphthalmia, coloboma, and skeletal
dysplasia versus isolated eye findings).32 Alternatively,
the recessive phenotype can be more severe than the
dominant phenotype, as with AARS ([MIM: 601065]
epileptic encephalopathy versus axonal CMT),40 DEAF1
([MIM: 602635] epilepsy, autism, and intellectual disability
versus nonsyndromic intellectual disability),41–43 and
EGR2 ([MIM: 129010] CMT versus congenital hypomyeli-
nating neuropathy).44,45 Notably, the dominant and reces-
sive forms of disease caused by a particular gene primarily
affect the same organ system(s), with the difference being
severity or additional associated features. Thus, caution
must be exercised in interpretation of novel variants that
do not conform to the expected inheritance pattern of
either a specific gene or a specific disorder (i.e., monoallelic
variants in GMNN [MIM: 602842] associated with Meier-
Gorlin syndrome, for which all other genes follow auto-
somal-recessive inheritance).46
Genotype-phenotype correlations can be associated
with different mutation types (missense versus nonsense,
i.e., RARB [MIM: 180220] and microphthalmia),47 mild
versus severe alleles (i.e., PMP22 [MIM: 601097] SNVs
and CMT),48 or localization of the mutations in specific
protein domains.49,50 Mutations in EGR2 (MIM: 129010)
affecting the zinc finger DNA-binding domain lead to a se-
vere, autosomal-dominant congenital hypomyelinating
neuropathy, whereas mutations outside this functional
region lead to an autosomal-recessive, less severe CMT.45
Similarly, heterozygous mutations in NALCN (MIM:
611549) found in specific pore-forming segments of the
encoded sodium channel lead to congenital contractures
of limbs and face, hypotonia, and developmental delay
(CLIFAHDD) syndrome, presumably via a dominant-
negative effect, whereas homozygous variants in other re-
gions lead to a less severe autosomal-recessive condition
characterized by hypotonia and intellectual disability.49
Allelic truncating mutations triggering or escaping NMD
can also modulate inheritance patterns.51–53 Classic reces-
sive b-thalassemia can be associated with prematurerican Journal of Human Genetics 98, 562–570, March 3, 2016 567
termination codons (PTCs) in the 50 region of the b-globin
gene, which trigger NMD, whereas mutations in the 30 re-
gion escape NMD and give rise to an atypical dominant
form of disease.52 Likewise, retinitis pigmentosa nonsense
mutations in the rhodopsin gene that trigger NMD result
in mild recessive alleles, whereas those that escape NMD
result in severe dominant alleles, presumably due to
toxicity of the truncated protein.54 In the case of EMC1,
one hypothesis might be that there is an important func-
tional domain yet to be identified in the vicinity of the
highly conserved amino acid altered by the de novo
p.Gly471Arg variant, rendering this variant more severe,
perhaps by perturbing the function of a complex via a
dominant-negative interaction. Identification and study
of additional families with disease-associated EMC1 vari-
ants, as well as functional studies, will help clarify the ge-
notype-phenotype correlation.
In conclusion, we define the phenotypic spectrum of
EMC1-associated disease, which includes global develop-
mental delay with marked speech delay, truncal hypotonia
with peripheral dystonic posturing and diminished DTRs,
scoliosis, abnormal ophthalmologic exam, and atrophy of
the brain primarily affecting the cerebellum. We hypothe-
size that EMC1 variants lead to a neurodegenerative process
by an as-yet-uncoveredmechanism, possibly involving pro-
tein folding or dysregulation of ER-mitochondria tethers,
and we provide evidence that EMC1 might lead to disease
via either a biallelic or monoallelic mechanism.Accession Numbers
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